Advertisement

Clinical utility of serum hepcidin and iron profile measurements in Alzheimer's disease

  • Author Footnotes
    1 Oh Joo Kweon and Young Chul Youn should be considered joint first author. These authors contributed equally to this work
    Oh Joo Kweon
    Footnotes
    1 Oh Joo Kweon and Young Chul Youn should be considered joint first author. These authors contributed equally to this work
    Affiliations
    Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 Oh Joo Kweon and Young Chul Youn should be considered joint first author. These authors contributed equally to this work
    Young Chul Youn
    Footnotes
    1 Oh Joo Kweon and Young Chul Youn should be considered joint first author. These authors contributed equally to this work
    Affiliations
    Department of Neurology, Chung-Ang University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Yong Kwan Lim
    Affiliations
    Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Mi-Kyung Lee
    Affiliations
    Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Hye Ryoun Kim
    Correspondence
    Corresponding author at: 224 1, Heukseok-Dong, Dongjak-Ku, Seoul 156 755, South Korea.
    Affiliations
    Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 Oh Joo Kweon and Young Chul Youn should be considered joint first author. These authors contributed equally to this work

      Highlights

      • AD patients had higher hepcidin values than MCI and normal controls.
      • The TIBC was significantly lower in the AD group than MCI and normal controls.
      • Serum iron levels were lower in the AD group than controls.
      • Hepcidin levels were statistically significantly correlated with the CDR.

      Abstract

      Objectives

      There are no generally accepted serum biomarkers for Alzheimer's disease (AD). We investigated the clinical usefulness of measuring the serum hepcidin levels and iron profile in patients with AD.

      Materials & methods

      The iron profile and hepcidin levels were measured in patients with AD (N = 70), minimal cognitive impairment (MCI, N = 39), and vascular dementia (VD, N = 25) and normal controls (N = 124). General cognitive tests were performed, and the relationships between cognition and hepcidin levels or the iron profile were assessed.

      Results

      Patients with AD had higher hepcidin values than those with MCI and VD and normal controls (median value: 39.00 vs. 30.81, 32.52, and 5.51 ng/ml, respectively, P < 0.001), and these differences were found in both men and women. The total iron-binding capacity was significantly lower in the AD group than in any other groups (308.0 vs. 332.0, 329.0, and 330.5 μg/dl, respectively, P = 0.018), and serum iron levels were lower in the AD group than controls (79.1 vs. 107.2 μg/dl, P = 0.007). Hepcidin levels were statistically significantly correlated with the clinical dementia rating (CDR, P = 0.040) with a Pearson's correlation coefficient of 0.253, and the patients with AD with a CDR value >1 had significantly higher hepcidin values than those with a CDR value of 1 (65.26 vs. 23.49 ng/ml, P = 0.020).

      Conclusion

      The measurement of serum hepcidin levels and the iron profile in patients with early manifestations of cognitive functional loss might aid in the diagnosis of AD and the assessment of disease severity when combined with other diagnostic parameters.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Grimm M.O.
        • Mett J.
        • Hartmann T.
        The impact of vitamin E and other fat-soluble vitamins on Alzheimer s disease.
        Int. J. Mol. Sci. 2016; 17
        • Selkoe D.J.
        Alzheimer's disease: genes, proteins, and therapy.
        Physiol. Rev. 2001; 81: 741-766
        • Oshiro S.
        • Morioka M.S.
        • Kikuchi M.
        Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
        Adv. Pharmacol. Sci. 2011; 2011: 8
        • Hardy J.
        • Selkoe D.J.
        The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
        Science (New York, N.Y.). 2002; 297: 353-356
        • Venkataramani V.
        • Doeppner T.R.
        • Willkommen D.
        • Cahill C.M.
        • Xin Y.
        • Ye G.
        • et al.
        Manganese causes neurotoxic iron accumulation via translational repression of amyloid precursor protein and H-ferritin.
        J. Neurochem. 2018; 147: 831-848
        • Shankar G.M.
        • Li S.
        • Mehta T.H.
        • Garcia-Munoz A.
        • Shepardson N.E.
        • Smith I.
        • et al.
        Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.
        Nat. Med. 2008; 14: 837-842
        • Zecca L.
        • Youdim M.B.
        • Riederer P.
        • Connor J.R.
        • Crichton R.R.
        Iron, brain ageing and neurodegenerative disorders.
        Nat. Rev. Neurosci. 2004; 5: 863-873
        • Ward R.J.
        • Zucca F.A.
        • Duyn J.H.
        • Crichton R.R.
        • Zecca L.
        The role of iron in brain ageing and neurodegenerative disorders.
        Lancet Neurol. 2014; 13: 1045-1060
        • Smith M.A.
        • Harris P.L.
        • Sayre L.M.
        • Perry G.
        Iron accumulation in Alzheimer disease is a source of redox-generated free radicals.
        Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 9866-9868
        • Yamamoto A.
        • Shin R.W.
        • Hasegawa K.
        • Naiki H.
        • Sato H.
        • Yoshimasu F.
        • et al.
        Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease.
        J. Neurochem. 2002; 82: 1137-1147
        • Sternberg Z.
        • Hu Z.
        • Sternberg D.
        • Waseh S.
        • Quinn J.F.
        • Wild K.
        • et al.
        Serum hepcidin levels, iron dyshomeostasis and cognitive loss in Alzheimer's disease.
        Aging Dis. 2017; 8: 215-227
        • Nemeth E.
        • Tuttle M.S.
        • Powelson J.
        • Vaughn M.B.
        • Donovan A.
        • Ward D.M.
        • et al.
        Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.
        Science (New York, N.Y.). 2004; 306: 2090-2093
        • Raha A.A.
        • Vaishnav R.A.
        • Friedland R.P.
        • Bomford A.
        • Raha-Chowdhury R.
        The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease.
        Acta Neuropathol. Commun. 2013; 1: 55
        • Donovan A.
        • Lima C.A.
        • Pinkus J.L.
        • Pinkus G.S.
        • Zon L.I.
        • Robine S.
        • et al.
        The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis.
        Cell Metab. 2005; 1: 191-200
        • Duce J.A.
        • Tsatsanis A.
        • Cater M.A.
        • James S.A.
        • Robb E.
        • Wikhe K.
        • et al.
        Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease.
        Cell. 2010; 142: 857-867
        • McCarthy R.C.
        • Kosman D.J.
        Mechanisms and regulation of iron trafficking across the capillary endothelial cells of the blood-brain barrier.
        Front. Mol. Neurosci. 2015; 8: 31
        • Tsatsanis A.
        • Dickens S.
        • Kwok J.C.F.
        • Wong B.X.
        • Duce J.A.
        Post translational modulation of beta-amyloid precursor protein trafficking to the cell surface alters neuronal iron homeostasis.
        Neurochem. Res. 2019; 44: 1367-1374
        • An S.S.A.
        • Lee B.S.
        • Yu J.S.
        • Lim K.
        • Kim G.J.
        • Lee R.
        • et al.
        Dynamic changes of oligomeric amyloid beta levels in plasma induced by spiked synthetic Abeta42.
        Alzheimers Res. Ther. 2017; 9: 86
        • Wang C.
        • Cui Y.
        • Yang J.
        • Zhang J.
        • Yuan D.
        • Wei Y.
        • et al.
        Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer's disease in patients with the apolipoprotein E 4 genotype.
        Biomarkers. 2015; 20: 84-88
        • Victor M.
        • S H.
        • Julia P.
        • Vasil V.
        • M P.
        • Latchezar T.
        • et al.
        The role of iron homeostasis in Alzheimer's disease.
        J. Alzheimers Neurodegener. 2017; 3
        • Armitage A.E.
        • Eddowes L.A.
        • Gileadi U.
        • Cole S.
        • Spottiswoode N.
        • Selvakumar T.A.
        • et al.
        Hepcidin regulation by innate immune and infectious stimuli.
        Blood. 2011; 118: 4129-4139
        • Christen Y.
        Oxidative stress and Alzheimer disease.
        Am. J. Clin. Nutr. 2000; 71 (621s–9s)
        • Huang W.J.
        • Zhang X.
        • Chen W.W.
        Role of oxidative stress in Alzheimer's disease.
        Biomed. Rep. 2016; 4: 519-522
        • Hare D.J.
        • Doecke J.D.
        • Faux N.G.
        • Rembach A.
        • Volitakis I.
        • Fowler C.J.
        • et al.
        Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation.
        ACS Chem. Neurosci. 2015; 6: 398-402
        • Ganz T.
        Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.
        Blood. 2003; 102: 783-788
        • Drakesmith H.
        • Prentice A.M.
        Hepcidin and the iron-infection axis.
        Science (New York, N.Y.). 2012; 338: 768-772
        • Pan Y.
        • Nicolazzo J.A.
        Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics.
        Adv. Drug Deliv. Rev. 2018; 135: 62-74
        • Janelidze S.
        • Hertze J.
        • Nagga K.
        • Nilsson K.
        • Nilsson C.
        • Wennstrom M.
        • et al.
        Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype.
        Neurobiol. Aging. 2017; 51: 104-112
        • Fischer P.
        • Gotz M.E.
        • Danielczyk W.
        • Gsell W.
        • Riederer P.
        Blood transferrin and ferritin in Alzheimer's disease.
        Life Sci. 1997; 60: 2273-2278
        • Pomara N.
        • Willoughby L.M.
        • Sidtis J.J.
        • Mehta P.D.
        Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report.
        Am. J. Geriatr. Psychiatr. 2005; 13: 914-917
        • Irizarry M.C.
        Biomarkers of Alzheimer disease in plasma.
        NeuroRx. 2004; 1: 226-234
        • Graff-Radford N.R.
        • Crook J.E.
        • Lucas J.
        • Boeve B.F.
        • Knopman D.S.
        • Ivnik R.J.
        • et al.
        Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
        Arch. Neurol. 2007; 64: 354-362
        • Mayeux R.
        • Honig L.S.
        • Tang M.X.
        • Manly J.
        • Stern Y.
        • Schupf N.
        • et al.
        Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk.
        Neurology. 2003; 61: 1185-1190
        • Xia W.
        • Yang T.
        • Shankar G.
        • Smith I.M.
        • Shen Y.
        • Walsh D.M.
        • et al.
        A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease.
        Arch. Neurol. 2009; 66: 190-199